Saturday 17 October 2026
Export ARQT’s income statement to Excel — free account
Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024. In the quarter to June 2026, revenue grew 59.3%, EPS grew 184.6%, free cash flow grew 228.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
28.82
0.28
−0.96%
Follow ARQT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 4 | 6 | 7 |
| (28.17%) | (9.30%) | (1.43%) | 15.86% | ||
| (10.97%) | (4.13%) | (0.59%) | 6.78% | ||
ROIC |
(31.79%) | (9.91%) | 2.69% | 23.62% | |
Return on Tangible Assets |
(17.68%) | (5.71%) | (0.86%) | 9.25% | |
Average Days of Receivables |
132.16 | 141.92 | 126.79 | 122.06 | |
Free Cash Flow per Share |
(0.38) | (0.17) | 0.21 | 0.30 | |
Free Cash Flow |
(48.24) | (21.31) | 26.99 | 39.07 | |
Capital Expenditures |
(15.69) | (15.69) | — | (0.24) | |
| Other line items | |||||
Cash ROIC |
(10.53%) | (4.10%) | 5.16% | 6.87% | |
Accounts Receivable Turnover |
3.63 | 3.43 | 3.62 | 3.54 | |
Accounts Payable Turnover |
2.54 | 2.74 | 1.76 | 3.79 | |
Inventory Turnover |
1.75 | 1.98 | 1.39 | 1.49 | |
Average Days of Payables |
66.28 | 124.61 | 177.38 | 58.65 | |
Days of Inventory on Hand |
256.42 | 225.14 | 362.50 | 345.31 | |
Tax Rate |
0.02 | 0.08 | 0.71 | (0.03) | |
Research and Development Expense of Revenue |
22.36% | 20.49% | 21.69% | 19.62% | |
Selling, General and Administrative Expense of Revenue |
79.64% | 73.01% | 68.48% | 64.14% | |
Share Based Compensation of Revenue |
12.49% | 10.73% | 9.93% | 9.39% | |
Interest Coverage |
(2.61) | (1.01) | 0.24 | 2.47 | |
Operating CF/Net income |
0.73 | 0.35 | (11.36) | 1.38 | |
Depreciation/Fixed assets |
1.00 | 2.47 | 0.80 | 1.50 | |
Capex/Depreciation |
(12.90) | (6.10) | 0.00 | (0.18) | |
Revenue per Share |
2.49 | 2.96 | 3.21 | 3.55 | |
Operating CF per Share |
(0.26) | (0.04) | 0.21 | 0.30 | |
Capex per Share |
(0.12) | (0.12) | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.04 | 0.00 | 0.00 |
Columns are period end dates